TOPICS 

    Subscribe to our newsletter

     By signing up, you agree to our Terms Of Use.

    FOLLOW US

    • About Us
    • |
    • Contribute
    • |
    • Contact Us
    • |
    • Sitemap
    封面
    NEWS

    Shanghai Sacks Two Scientists Over Child’s Death in Gene Trial

    A Shanghai investigation found failures across the research and hospital approval process, including unshared safety warnings, inadequate scrutiny of risks, and undisclosed payments and gifts from the child’s family.
    Nov 16, 2026#science#health

    Shanghai authorities have dismissed two researchers after an investigation into a child’s death following experimental gene-editing treatment found unheeded safety warnings, failures in ethical review, and undisclosed payments and gifts from the family.

    The child had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder with no effective treatment, according to findings released Friday by the Shanghai investigation team. The family contributed 5.3 million yuan ($800,000) toward the research and separately gave researchers approximately 1.06 million yuan in money and gifts.

    In July 2023, the family approached Qiu Zilong, deputy director of Shanghai Jiao Tong University School of Medicine’s Songjiang Research Institute, hoping his team could develop a customized gene-editing treatment, investigators said.

    The child received an injection at the university’s affiliated Xinhua Hospital on March 24, 2025, and died seven days later.

    At an emergency review April 2, the hospital’s ethics committee attributed the death to thrombotic microangiopathy, a complication of gene therapy, and ordered the study terminated.

    The death went unmentioned in related preclinical research Qiu’s team published in Nature in February 2026, investigators said. The team reported using gene editing to correct a single error in the DNA code of mouse brain cells, restoring levels of a protein essential for normal brain development. The researchers said tests in monkeys also suggested the technique’s potential for use in humans.

    Five months later, a joint investigation by Science and Retraction Watch revealed the fatal human trial and reported that the Nature paper had also omitted evidence of liver and kidney damage in animal safety tests.

    Shanghai authorities subsequently established a team to investigate the preclinical research, the hospital’s clinical study, and the data underlying the Nature paper.

    Investigators found that Qiu’s team had failed to promptly share a safety report from experiments on nonhuman primates with the clinical study’s lead investigator, leaving warning signals unheeded.

    Xinhua Hospital’s ethics committee approved the study despite insufficient toxicology and safety evidence, proceeding without additional material it had requested. The hospital also failed to independently and adequately assess the study’s scientific basis and safety.

    Investigators said that although the consent form warned the family of serious complications and adverse events, it did not prominently communicate the risk of death.

    Investigators found no data fabrication in the Nature paper but identified discrepancies between the research methods used and those described. Data from the same experimental batch had also been presented separately without explanation.

    The Nature paper also failed to disclose financial conflicts involving four researchers. Qiu received expensive liquor and electronics worth approximately 100,000 yuan, while Xinhua Hospital associate researcher Yang Kan, the Nature paper’s first and corresponding author, received 900,000 yuan and expensive liquor. Two other members of Qiu’s team each received 30,000 yuan.

    Investigators said the money and gifts had been returned or surrendered in accordance with regulations.

    Qiu and Yang were both dismissed, and barred from participating in science and technology programs and awards for five years. Their names were entered into a database of serious research integrity violations.

    The clinical study’s lead investigator, surnamed Yu, was removed as head of Xinhua Hospital’s research department and demoted. Yu was also barred for five years from being promoted, participating in science and technology programs and awards, and recruiting graduate students. Another official, surnamed Shi, was removed as head of the hospital’s ethics committee office and demoted.

    Other officials responsible for the hospital’s ethics review and research oversight received disciplinary sanctions. Xinhua Hospital received an administrative penalty, which the investigation team did not detail.

    The Shanghai Municipal Health Commission said it would soon launch special inspections of clinical research involving emerging biomedical technologies.

    “As biomedical technologies advance rapidly, research institutions and practitioners must recognize the high risks associated with clinical studies involving emerging treatments such as cell and gene therapies,” the probe said. “While pursuing innovation, they must also adhere to professional standards.”

    Editor: Apurva.

    (Header image: iStock/VCG)